Discover the interview with Pr. James Robinson by Lise Rochaix about his newly released Health Affairs paper on drug price competition and the role of biosimilars.
As Professor of health economics in the School of Public Health at the University of California, Berkeley, and chair of both the Leonard D. Schaeffer Endowed Chair in Health Economics and Policy and the Berkeley Center for Health Technology, you have a keen interest in research related to coverage, management, and payment methods for innovative technologies including biopharmaceuticals, medical devices, and diagnostics. During your visit in France in December 2019, and your presentation at the joint Hospinnomics and LIRAES seminar, you had the opportunity to meet with stakeholders and get acquainted with the complexities of the French drug price negotiation scheme. You have recently published your results in Health Affairs, jointly with Quentin Jarrion and I would like to ask you three questions:
- Why do you think the French experience should be of relevance to the United-States?
- Which are the most striking results from your study on the French drug market?
- Which first step should be taken to yield similar benefits in the United-States?
Access the interview here.
Access Pr. Robinson’s biography.